AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,780.00p
   
  • Change Today:
    -118.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.29m
  • Volume: 3,460,879
  • Market Cap: £182,624m
  • RiskGrade: 123

US FDA gives green light for use of AstraZeneca's Voydeya

By Alexander Bueso

Date: Wednesday 03 Apr 2024

LONDON (ShareCast) - (Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).
PNH is a condition under which some patients' immune systems destroy a larger proportion of red blood cells than they should, whilst EVH is the condition in which red blood cells outside of blood vessels were destroyed.

Voydeya could now be used as an add-on therapy to ravulizumab or eculizumab to treat EVH in adults with PNH.

The drug was a first-in-class, oral, Factor D inhibitor meant to address the needs of the roughly 10-20% of patients with PNH experiencing "clinically significant" EVH when they were being treated with a C5 inhibitor.



Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,780.00p
Change Today -118.00p
% Change -0.99 %
52 Week High 13,276.00
52 Week Low 9,501.00
Volume 3,460,879
Shares Issued 1,550.29m
Market Cap £182,624m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.44% below the market average92.44% below the market average92.44% below the market average92.44% below the market average92.44% below the market average
95.92% below the sector average95.92% below the sector average95.92% below the sector average95.92% below the sector average95.92% below the sector average
Price Trend
56.23% above the market average56.23% above the market average56.23% above the market average56.23% above the market average56.23% above the market average
79.59% above the sector average79.59% above the sector average79.59% above the sector average79.59% above the sector average79.59% above the sector average
Income
89.61% below the market average89.61% below the market average89.61% below the market average89.61% below the market average89.61% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Growth
88.03% above the market average88.03% above the market average88.03% above the market average88.03% above the market average88.03% above the market average
93.94% above the sector average93.94% above the sector average93.94% above the sector average93.94% above the sector average93.94% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 20-Sep-2024

Time Volume / Share Price
16:47 217 @ 11,780.00p
16:45 217 @ 11,780.00p
16:42 248 @ 11,780.00p
16:42 1 @ 11,780.00p
16:42 1,240 @ 11,780.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page